搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
6 小时
Latest fundraise points to undiminished appetite for AI in life sciences
California-based AI firm Suki has raised $70 million in new funding, led by Hedosophia, bringing its total to $165 million.
The Pharma Letter
6 小时
Uncertain future for S1P receptor modulators in Crohn’s disease, says GlobalData
Pfizer is set to present initial findings from its CULTIVATE study of Velsipity (etrasimod) in Crohn’s disease (CD) at UEG ...
The Pharma Letter
7 小时
Sandoz launches first FDA-approved generic of Abraxane
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in ...
The Pharma Letter
6 小时
KeyBioscience and Lilly go back for more
Switzerland-based KeyBioscience and US pharma major Eli Lilly have extended their collaboration on dual amylin calcitonin ...
The Pharma Letter
23 小时
Leo Pharma announces another round of job cuts
Danish dermatology specialist Leo Pharma has revealed plans to cut more jobs, marking the company’s fourth workforce ...
The Pharma Letter
12 小时
UK approves new Comirnaty jab targeting latest subvariant
The UK's MHRA has approved Pfizer and BioNTech's updated COVID-19 vaccine, Comirnaty (KP.2), for use in adults. This approval ...
The Pharma Letter
23 小时
CAMP4's turn to "dark side" shows promise, with $75 million IPO
Cambridge, Massachusetts-based RNA specialist CAMP4 Therapeutics (Nasdaq: CAMP) is set to raise $75 million as it goes public ...
The Pharma Letter
12 小时
Booster Therapeutics emerges from stealth
Berlin, Germany-based Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines ...
The Pharma Letter
11 小时
FDA approves Genentech’s Itovebi for PIK3CA-mutated mBC
The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...
The Pharma Letter
12 小时
Immunotherapy firm Immatics prices $150 million public offering
German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...
The Pharma Letter
12 小时
Samsung Bioepis’ latest US biosimilar market report
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of ...
The Pharma Letter
6 小时
Teva to pay $450 million in False Claims Act settlement
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈